Regeneron and Sanofi Present Results of Libtayo (cemiplimab) in P-III EMPOWER-Lung 3 Study as 1L Treatment of Advanced NSCLC at ESMO 2021
Shots:
- The P-III EMPOWER-Lung 3 study evaluates Libtayo (350mg- q3w for 108wks.) + Pt doublet CT vs CT alone in a ratio (2:1) in 466 patients with LA/mNSCLC irrespective of histology & across all PD-L1 expression levels- 84% had an ECOG 1 performance status
- The trial met its 1EPs & 2EPs i.e.- improvement in OS in an overall population; m-OS (22 vs 13mos.) with 29% reduction in risk of death; probability of survival & PFS (66% & 56%) & (38% & 16%) @12mos; m-PFS (8 vs 5mos.) with 46% reduction in risk of disease progression; ORR (43% vs 23%) & m-DoR (16 vs 7mos.)
- The therapy has improved pain symptoms- favorable PRO’s & no new safety signals observed. The median duration of exposure (38 & 21wks.)
| Ref: PR Newswire | Image: Investors Business Daily
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com